Israel Ends Prescribing Ban On Viagra
Israel's Health Ministry is ending its ban on prescribing Pfizer'simpotence drug Viagra (sildenafil), which was imposed pending US Food and Drug Administration and Pfizer go-aheads for continued use and details of contraindications after the deaths of six men who took the drug (Marketletter June 1).
The Ministry is again permitting doctors to prescribe the drug, available in Israel only by personal import, according to Joshua Shemer, the Health Ministry's associate director general for medical technology and infrastructure, reported by Reuters. This means a patient with a prescription for Viagra must receive approval from the Ministry's district pharmacist.
The drug has not yet been approved in Israel, said Mr Shemer, noting that Pfizer had not yet filed a formal request to sell Viagra there. Once Pfizer or its local importer files such a request, the Israeli Ministry will evaluate the drug, although Mr Shemer noted that the Ministry relies strongly on the FDA's opinion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze